Lymph node CEA and MUC2 mRNA as useful predictors of outcome in colorectal cancer
(2012) In International Journal of Cancer 130(8). p.1833-1843- Abstract
- The aim was to explore the utility for staging and prognostic impact of carcinoembryonic antigen (CEA), cytokeratin 20 (CK20), guanylyl cyclase C (GCC), CUB (complement protein subcomponents C1r/C1s, urchin embryonic growth factor, and bone morphogenic protein 1) containing domain protein 1 (CDCP1) and mucin 2 (MUC2) mRNA levels in mesenteric lymph nodes of colorectal cancer (CRC) patients. Lymph nodes were collected at surgery and bisected; one half was subjected to biomarker mRNA analysis using real-time quantitative RT-PCR and the other half to routine histopathology. Lymph nodes from 174 CRC patients and 24 controls were analyzed. The median follow-up time was 59 (range 17-131) months. Cut-off levels were defined by analyzing quintiles... (More)
- The aim was to explore the utility for staging and prognostic impact of carcinoembryonic antigen (CEA), cytokeratin 20 (CK20), guanylyl cyclase C (GCC), CUB (complement protein subcomponents C1r/C1s, urchin embryonic growth factor, and bone morphogenic protein 1) containing domain protein 1 (CDCP1) and mucin 2 (MUC2) mRNA levels in mesenteric lymph nodes of colorectal cancer (CRC) patients. Lymph nodes were collected at surgery and bisected; one half was subjected to biomarker mRNA analysis using real-time quantitative RT-PCR and the other half to routine histopathology. Lymph nodes from 174 CRC patients and 24 controls were analyzed. The median follow-up time was 59 (range 17-131) months. Cut-off levels were defined by analyzing quintiles by Cox regression model. CEA mRNA showed the best discriminating power between patients with recurrence in CRC after surgery and patients who were apparently disease-free (p = 0.015). The risk of recurrence for the CEA(+) patients was 4.6 times greater than for the CEA(-) patients (p < 0.0001). The other biomarkers gave lower hazard ratios. Cumulative survival analysis demonstrated that the average survival time was 99 months for CEA(-) patients compared to 39 months for CEA(+) patients, a difference of 60 months (p < 0.0001). Six to nine percent of the Stage I and Stage II patients [H&E(-)] had CEA(+), CK20(+), GCC(+) and/or MUC2(+) lymph nodes. Two of these patients died from recurrent CRC. Low lymph node MUC2/CEA mRNA ratio identified patients with high risk for recurrence (p = 0.011). Thus, quantitative reverse transcriptase-polymerase chain reaction of CEA mRNA is a sensitive method to identify tumor cells in lymph nodes of CRC patients and, in combination with MUC2 mRNA, allows improved prediction of clinical outcome. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2378728
- author
- Ohlsson, Lina ; Israelsson, Anne ; Oberg, Ake ; Palmqvist, Richard ; Stenlund, Hans ; Hammarstrom, Marie-Louise ; Hammarstrom, Sten and Lindmark, Gudrun LU
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- colorectal neoplasms, lymphatic metastasis, neoplasm staging, prognosis, qRT-PCR
- in
- International Journal of Cancer
- volume
- 130
- issue
- 8
- pages
- 1833 - 1843
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- wos:000300692300013
- scopus:84857505150
- pmid:21618511
- ISSN
- 0020-7136
- DOI
- 10.1002/ijc.26182
- language
- English
- LU publication?
- yes
- id
- 0fee59da-56c5-4cc1-9be3-ba2dd5e14cbf (old id 2378728)
- date added to LUP
- 2016-04-01 11:08:03
- date last changed
- 2022-01-26 05:44:36
@article{0fee59da-56c5-4cc1-9be3-ba2dd5e14cbf,
abstract = {{The aim was to explore the utility for staging and prognostic impact of carcinoembryonic antigen (CEA), cytokeratin 20 (CK20), guanylyl cyclase C (GCC), CUB (complement protein subcomponents C1r/C1s, urchin embryonic growth factor, and bone morphogenic protein 1) containing domain protein 1 (CDCP1) and mucin 2 (MUC2) mRNA levels in mesenteric lymph nodes of colorectal cancer (CRC) patients. Lymph nodes were collected at surgery and bisected; one half was subjected to biomarker mRNA analysis using real-time quantitative RT-PCR and the other half to routine histopathology. Lymph nodes from 174 CRC patients and 24 controls were analyzed. The median follow-up time was 59 (range 17-131) months. Cut-off levels were defined by analyzing quintiles by Cox regression model. CEA mRNA showed the best discriminating power between patients with recurrence in CRC after surgery and patients who were apparently disease-free (p = 0.015). The risk of recurrence for the CEA(+) patients was 4.6 times greater than for the CEA(-) patients (p < 0.0001). The other biomarkers gave lower hazard ratios. Cumulative survival analysis demonstrated that the average survival time was 99 months for CEA(-) patients compared to 39 months for CEA(+) patients, a difference of 60 months (p < 0.0001). Six to nine percent of the Stage I and Stage II patients [H&E(-)] had CEA(+), CK20(+), GCC(+) and/or MUC2(+) lymph nodes. Two of these patients died from recurrent CRC. Low lymph node MUC2/CEA mRNA ratio identified patients with high risk for recurrence (p = 0.011). Thus, quantitative reverse transcriptase-polymerase chain reaction of CEA mRNA is a sensitive method to identify tumor cells in lymph nodes of CRC patients and, in combination with MUC2 mRNA, allows improved prediction of clinical outcome.}},
author = {{Ohlsson, Lina and Israelsson, Anne and Oberg, Ake and Palmqvist, Richard and Stenlund, Hans and Hammarstrom, Marie-Louise and Hammarstrom, Sten and Lindmark, Gudrun}},
issn = {{0020-7136}},
keywords = {{colorectal neoplasms; lymphatic metastasis; neoplasm staging; prognosis; qRT-PCR}},
language = {{eng}},
number = {{8}},
pages = {{1833--1843}},
publisher = {{John Wiley & Sons Inc.}},
series = {{International Journal of Cancer}},
title = {{Lymph node CEA and MUC2 mRNA as useful predictors of outcome in colorectal cancer}},
url = {{http://dx.doi.org/10.1002/ijc.26182}},
doi = {{10.1002/ijc.26182}},
volume = {{130}},
year = {{2012}},
}